The professor of Pharmacoepidemiology at the University of Oxford, Daniel Prieto-Alhambra, trusts that by the end of the year the anti-COVID-19 vaccine that scientists from this British university center are developing will be approved and that vaccinations begin the first quarter of 2021.
In an interview in RAC-1, Prieto-Alhambra has been optimistic about the vaccine and has indicated that, despite the worsening of the epidemiological situation, “We are in a much better situation than in March, but we want to avoid that situation.” That is why he has defended taking action, although “It must not be the confinements. The confinements are the ICU of the measures. We have to find others that are not so restrictive. “
“What is being done now in Catalonia is correct.The virus runs faster than we would like and, if we do not act in time, we can have problems. The countries where it has done better are those that have done things very quickly, “said the pharmacoepidemiologist.
“I am very sorry for the dichotomy between health and the economy, but it is artificial. If what must be done is not done now, within a month a severe confinement will have to be done and the economic impact will be greater,” he warned
They hope to start vaccinating in 2021
On the flu epidemic that could coexist with the SARS-Cov-2 virus, the professor said: “The only thing we know so far is what we have learned from the southern hemisphere, especially from Australia. There a good combination of vaccines has served to minimize the flu epidemic. We hope people get vaccinated and work here too. “
Regarding the fight against the new coronavirus, Prieto-Alhambra does not believe that “herd immunity” can be achieved and relies more on the vaccine.
“The best situation would be for the vaccine to be approved by the end of the year and vaccination could begin in the first quarter of 2021,” concluded the Oxford professor.
The vaccine is delayed
More and more pharmaceutical companies are postponing their distribution date. This Monday the news was made public that the multinational ‘Johnson & Johnson ‘- one of those working on the vaccine against the virus – has stopped trials of the vaccine for an “unexplained illness” in a participant.
Following repeated praise from US President Donald Trump, the pharmacist ‘Eli Lilly’ suspended this Tuesday the tests with his therapy COVID-19 antibody test due to safety concerns.
On the other hand, Russian ‘Sputnik V’ vaccine has already started to be tested in people over 60 years, but they do not expect to have vaccinated 80% of their population for 9 to 12 months.
Nor will the laboratory vaccines be ready to distribute this year AstraZeneca, Pfizer and CanSino. The Government of Mexico signed a purchase agreement with the three laboratories, to begin receiving, from December and during the next year, about 140 million doses of vaccines against COVID-19 in case their effectiveness is verified.
The French pharmaceutical group ‘Sanofi’ works on a coronavirus vaccine project for which you have scheduled an accelerated production start to be available in the middle of next year. “Our goal is to have a vaccine by the middle of next year “, The president of Sanofi in France, Olivier Bogillot, stressed this Tuesday in an interview with the station ‘France Info’.
The World Health Organization (WHO) has counted a total of 40 vaccine candidates, some of which are in clinical trials. But only 10 have gone to phase 3; a figure that they describe as “encouraging”, although they do not expect to have an effective vaccine until December 2020 and early 2021.